The ctDNA MRD Detection Paradigm Shift in Early-Stage Solid Cancers

Wednesday February 17, 2021 | 8:00am PST | 11:00am EST

Engager Hosted by

Inivata cropped

The February Inivata Engager will cover:

The ctDNA MRD Detection Paradigm Shift in Early-Stage Solid Cancers

Welcome to the Inivata Engager, an exclusive event providing leaders in academia, pharma and biotech with the opportunity to explore how MRD assays can provide a dynamic measure of treatment effectiveness and an earlier identification of potential relapse in early-stage solid cancers.

Providing perspectives from leading experts in the field, join this Engager to learn about the benefits of using MRD assays in clinical trials and discuss how they can be used to enrich group testing of new therapies. Delve into the advantages of using ctDNA approaches for both clinical trial selection and monitoring, and how they can provide complimentary information in differential clinical trial applications.


Sabine Tejpar

Associate Professor - Department of Gastro Enterology, Digestive Oncology Unit

UZ Leuven

Stefan Scherer

Medical Advisor


Tim Forshew

Head of Science & Innovation & Co-Founder


Tina Tan

Executive Editor

FirstWord HealthTech


  • Discuss how the paradigm for MRD detection is changing with new applications in both detection of residual disease and monitoring during and after treatment
  • Outline and review opportunities for new clinical trial designs
  • Discuss the potential impact of this approach to clinical practice


Following a Q&A, attendees can connect with key Inivata executives and members to converse and dig a bit deeper into the topics covered throughout the session.


This is an event for senior executives from biopharmas involved in designing clinical trials within the oncology space and looking to get an overview of ctDNA MRD assays, understand how they can be used to improve clinical trial designs and explore the advantages of using ctDNA approaches in different clinical trial applications.

This digital event will bring different perspectives from leading experts to help understand how ctDNA MRD assays are currently used and how they can be implemented into your clinical trials.


Inivata cropped

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available internationally and through NeoGenomics in the US. It offers competitive sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK.

For more information, please go to Follow Inivata on Twitter @Inivata